After Blowing The Whistle On Theranos, Tyler Shultz Is Going Back Into Medical Testing | Forbes https://t.co/wYUDEsePs7
9:10am October 5th 2017 via Hootsuite
Inova Health System unveils new consumer genome sequencing offering via Veritas - Washington Business Journal https://t.co/NoaNWVQ9PS
8:10am October 5th 2017 via Hootsuite
Personal Genetic Testing Is Here. Do We Need It? | NYT https://t.co/pxy1lMiX07
6:58am October 5th 2017 via Hootsuite
The World’s 1st Molecular Robot Has Just Been Created by UK Scientists | Big Think https://t.co/vIaX2VmOFK
10:15pm October 4th 2017 via Hootsuite
Google and Facebook Have Failed Us - The Atlantic https://t.co/pZuB66Kvmj
8:45pm October 4th 2017 via Hootsuite
Your Birth Month Can Determine What Diseases You’ll Likely Develop | Big Think https://t.co/5ByIkvXybq
7:45pm October 4th 2017 via Hootsuite
Google and Facebook Have Failed Us - The Atlantic https://t.co/NTocCBEcC1
5:20pm October 4th 2017 via Hootsuite
Great to meet many at #genomicsfest - thank you to all who came up to say 'hi'!
4:15pm October 4th 2017 via Hootsuite
Crompton: Still need more ways to target cancer, more Rx. #genomicsfest
3:57pm October 4th 2017 via Hootsuite
Chevillet: Will see key applications - this tumor, this mutation, this Rx. EGFR resistance has been approved #genomicsfest
3:56pm October 4th 2017 via Hootsuite
Thorner: 5y? Reddi: Being able to draw correlates, from dx or prognostic perspective, where non-invasive tests become norm #genomicsfest
3:55pm October 4th 2017 via Hootsuite
Q: Anyone working to maximize pts' ctDNA content? Chevillet: One study - vigorous exercise, found muscle markers increase #genomicsfest
3:52pm October 4th 2017 via Hootsuite
Crompton: Easier to get a blood smpl; lots of pts are going to go ahead and buy it. Pts want their physicians to get all info #genomicsfest
3:51pm October 4th 2017 via Hootsuite
Reddi: Liquid biopsy isn't reimbursed yet, too new. What about VUS's? What does it mean? Solid tumor can't extrapolate to LB #genomicsfest
3:50pm October 4th 2017 via Hootsuite
Q: Guardant360 is 73; FMI is 62 genes; how will panels be adopted? Reddi: It is driven by reimb. <50 genes reimb much higher #genomicsfes
3:49pm October 4th 2017 via Hootsuite
Crompton: Tissue of origin - could be coupled with CTCs and IHC; perhaps looking at breakpoints and open chromatin for origin #genomicsfest
3:47pm October 4th 2017 via Hootsuite
Crompton: Rare subclonal TK can become dom. at time of relapse. Only way to know is more ctDNA studies. Relapse not looked at #genomicsfest
3:46pm October 4th 2017 via Hootsuite
Crompton: Answer to that is unknowable. Hint from leukemia: bone marrow from pediatric smpls - see subclonal TK events #genomicsfest
3:45pm October 4th 2017 via Hootsuite
Thorner: What about MAF that's low? Reddi: What does 0.2% mean to a pt? Heterogeneity, thus their LOD set at 1% #genomicsfest
3:44pm October 4th 2017 via Hootsuite
Reddi: Narrowed down to a handful (14) genes. What are most common cancers, most common variants. Also actionability #genomicsfest
3:43pm October 4th 2017 via Hootsuite
Q: Det cancer type? What genes, types of muts? Reddi: Looked at 2y of gene-panel results; checked against literature #genomicsfest
3:42pm October 4th 2017 via Hootsuite
Crompton: Li-Fraumeni, is 60% risk, could use liquid biopsy for freq monitoring. Problem to know what to look for, potential #genomicsfest
3:40pm October 4th 2017 via Hootsuite
Q: Liquid biopsies used proactively (screening)? Crompton: No data at all - 'very excited about it'. Pts with predisposition #genomicsfest
Reddi: QIAGEN putting resources into preanalytical variables. What is the best method as 'truth'. #genomicsfest
3:39pm October 4th 2017 via Hootsuite
Chevillet: Raises a good point - where skin cells are accidently collected in a blood draw, where epithelial CTC markers used #genomicsfest
3:38pm October 4th 2017 via Hootsuite
Thorner: Standardization of collection? Reddi: Starting-point can all be arguable; tumor cellularity in FFPE? #genomicsfest
3:36pm October 4th 2017 via Hootsuite
Crompton: Can imagine the day where resistance is actively monitored, managed like HIV. #genomicsfest
3:35pm October 4th 2017 via Hootsuite
Q: Where is the most interesting dev? Crompton: For ctDNA, the clinical prognostic outcome. #genomicsfest
3:34pm October 4th 2017 via Hootsuite
Chevillet: Unk where the most useful biomarker will be - in exosomes, in CTCs, in ctDNA. 'We have to show it.' #genomicsfest
3:32pm October 4th 2017 via Hootsuite
Chevillet: But CTC selection is a problem. MicroRNAs thought to be encapsulated and then it wasn't true. #genomicsfest
Crompton: How to control for CTCs in ctDNA samples? At 0.1%, it all matters. Chevillet: Ways to select for / against CTCs #genomicsfest
3:30pm October 4th 2017 via Hootsuite
Reddi: Not easy to transfer NIPT over to cancer; many more considerations. #genomicsfest
3:29pm October 4th 2017 via Hootsuite
Thorner: Could it be used upfront? Crompton: Need to know clinical goal. ctDNA in all tumor types except for transloc (>50%) #genomicsfes
3:26pm October 4th 2017 via Hootsuite
Crompton: Ped ca driven by transloc and CNV; not hotspots. Thornton: How looking at CNV? A:WGS and Broad CNV caller #genomicsfest
3:25pm October 4th 2017 via Hootsuite
Chevillet: Tec-Seq paper to exceed error rate - barcode molecules, amplify, '17 ref https://t.co/AVXsLZtHZD #genomicsfest
3:23pm October 4th 2017 via Hootsuite
Reddi: Also plasma samples from collaborators. Thorner: How to exceed limit of accuracy of NGS? Reddi: use ddPCR to confirm #genomicsfest
3:21pm October 4th 2017 via Hootsuite
Reddi: They have to consider patient needs, foremost. Thorner: how is LOD est? A: Known samples, from SeraCare or Horizon. #genomicsfest
3:20pm October 4th 2017 via Hootsuite
Reddi: Their lowest input was 1mL of plasma, 10ng of cfDNA. At 20,000x coverage, set LOD at 1% from a clinical utility persp #genomicsfest
Chevillet: Lots of different problems - monitoring therapy, screening. May well have multiple methods of interrogation. #genomicsfest
3:18pm October 4th 2017 via Hootsuite
Thorner: How do you know you have enough cfDNA? Crompton: his patients 'are small'. Pairing blood draw w/apheresis, not real #genomicsfest
3:16pm October 4th 2017 via Hootsuite
Brian Crompton (Dana Farber) Pediatric oncologist, runs a translational research lab. Not engineers, implementing est tech #genomicsfest
3:13pm October 4th 2017 via Hootsuite
John Chevillet (Draper Labs MA) Spun out of MIT years ago, dev microfluidic tech for CAR-T therapy, currently $500K #genomicsfest
3:11pm October 4th 2017 via Hootsuite
Reddi: two cancer panels, a fusion panel, near final validation of a liquid biopsy assay. Partnerships with academics, pharma #genomicsfest
3:10pm October 4th 2017 via Hootsuite
Panel: Honey Reddi (Jackson Labs) John Chevillet (Draper) Brian Crompton (Dana Farber) Reddi: Jackson 'one campus w/o mice' #genomicsfest
3:09pm October 4th 2017 via Hootsuite
Thorner: His group optimizes assays, and deploys them into the clinic. Sequenom 10y ago; Oncopanel for NGS #genomicsfest
3:08pm October 4th 2017 via Hootsuite
Aaron Thorner (Cancer Genome Discovery, Dana Farber) Realizing the potential of liquid biopsies: are we ready? #genomicsfest
3:07pm October 4th 2017 via Hootsuite
Q: Cofactor had 14 investors at seed. Ideal number? Messina: Quality over quantity; those truly invested in you #genomicsfest
2:16pm October 4th 2017 via Hootsuite
Q: How did you find investors to talk with? Messina: people you know; companies list who invest in them; also investor conf's #genomicsfest
2:13pm October 4th 2017 via Hootsuite
Messina: Do you really need slides? You want engagement. It's a 2-way conversation. You are looking to enter a relationship. #genomicsfest
2:10pm October 4th 2017 via Hootsuite
Messina: 'If you are doing most of the talking, you are doing it wrong.' You need to hear from them as much as you say. #genomicsfest
2:09pm October 4th 2017 via Hootsuite
